| Literature DB >> 27256135 |
Gary E Marchant1, Kathryn Scheckel1, Doug Campos-Outcalt1.
Abstract
As the health care system transitions to a precision medicine approach that tailors clinical care to the genetic profile of the individual patient, there is a potential tension between the clinical uptake of new technologies by providers and the legal system's expectation of the standard of care in applying such technologies. We examine this tension by comparing the type of evidence that physicians and courts are likely to rely on in determining a duty to recommend pharmacogenetic testing of patients prescribed the oral anti-coagulant drug warfarin. There is a large body of inconsistent evidence and factors for and against such testing, but physicians and courts are likely to weigh this evidence differently. The potential implications for medical malpractice risk are evaluated and discussed.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27256135 PMCID: PMC5137582 DOI: 10.1177/1073110516644210
Source DB: PubMed Journal: J Law Med Ethics ISSN: 1073-1105 Impact factor: 1.718